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Background: Epimedii herba is one of the most frequently used herbs in formulas that are prescribed for the
treatment of osteoporosis in China and its main constituent is Epimedium pubescen flavonoid (EPF). However, it is
unclear whether EPF during chronic exposure to cigarette smoke may have a protective influence on the skeleton.
The present study investigated the effect of EPF on bone mineral status and bone turnover in a rat model of
human relatively high exposure to cigarette smoke.
Methods: Fifty male Wistar rats were randomized into five groups: controls, passive smoking groups and passive
smoking rats administered EPF at three dosage levels (75, 150 or 300 mg/kg/day) in drinking water for 4 months.
A rat model of passive smoking was prepared by breeding male rats in a cigarette-smoking box. Bone mineral
content (BMC), bone mineral density (BMD), bone turnover markers, bone histomorphometric parameters and
biomechanical properties were examined.
Results: Smoke exposure decreased BMC and BMD, increased bone turnover (inhibited bone formation and
stimulated its resorption), affected bone histomorphometry (increased trabecular separation and osteoclast
surface per bone surface; decreased trabecular bone volume, trabecular thickness, trabecular number, cortical
thickness, bone formation rate and osteoblast surface per bone surface), and reduced mechanical properties.
EPF supplementation during cigarette smoke exposure prevented smoke-induced changes in bone mineral
status and bone turnover.
Conclusion: The results suggest that EPF can prevent the adverse effects of smoke exposure on bone by
stimulating bone formation and inhibiting bone turnover and bone resorption.
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Bone histomorphometryBackground
Recent epidemiological studies have yielded increasingly
strong evidence that even low level of tobacco smoke
exposure poses a risk for health, particularly affecting
the lung and skeleton [1-12]. Smoking was also asso-
ciated with lower areal BMD and reduced cortical thick-
ness in young men [13]. Systemic nicotine may have a* Correspondence: lgh9640@gmail.com
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reproduction in any medium, provided the orsignificant adverse impact on bone wound healing and
inhibit the bone matrix-related gene expressions required
for wound healing [14,15].
Tobacco has been identified as the cause for the death
of half of its regular users, but insufficient consideration
has been given to the hazard of smoking to passive
smokers. Thus, a growing interest has been focused on
factors that can protect from the harmful action of
cigarette smoke.
Epimedii herba (Yinyanghuo) is one of the most fre-
quently used herbs in formulas that are prescribed for
the treatment of osteoporosis in China and its main. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Recently, EPF which consist of three phytoestrogenic
compounds (Icariin, Genistein and Daidzein), has been
fractioned by a series of standardized extraction-
isolation procedures. Studies have shown the extract of
Epimedii herba reduces the occurrence of osteoporosis
not only in experimental models [16,17] but also in clin-
ical studies [18].
It is unclear whether EPF during chronic exposure to
cigarette smoke may have a protective influence on
the skeleton. Therefore, this study was designed to
evaluate the effects of EPF on BMD, BMC, bone turn-
over, bone histomorphometry and biomechanical prop-
erties in a rat model of human relatively high exposure
to cigarette smoke.
Methods
Animals and experimental protocol
Fifty adult 8-month-old (body weight 352 ± 24 g) male
Wistar rats were purchased from SLRC Laboratory
Animal (Shanghai, China). The experiment was per-
formed with the approval of the Animal Research Com-
mittee of the Xiangya Hospital, and the animals were
cared for in the Experimental Animal Center of Xiangya
Hospital. During the whole experiment the animals were
housed in stainless steel cages (one rat per cage) at con-
ventional controlled conditions (temperature 25 ± 2°C,
relative humidity of 50 ± 10%, 12 h light–dark cycle) and
had free access to the standard laboratory food and
tap water.
The rats were acclimated to conditions for one week
before the experiment and randomly assigned to five
groups of 10 rats each. One group drank tap water and
it served as a control. The smoke-exposed groups were
kept in an environment with smoking for 4 months
and it served as passive smoking groups, whereas the
remaining three groups were supplemented with EPF
during exposure to cigarette smoke. EPF (Jiuhui
pharmaceutical Corp., Hunan, China) was administered
at three dosage levels (75, 150 or 300 mg/kg per day)
in drinking water for 4 months and expressed as L-EPF,
M-EPF, and H-EPF.
Cigarette smoking
The rats were exposed to sidestream cigarette smoke
(CS) from an ashtray which was placed 10 cm below the
rat cage in an exposure box (30 cm×5 cm× 15 cm)
made of polypropylene, which was placed in a laboratory
draft chamber [19]. Using this equipment, the time,
amount, and interval of smoke to be sent into the cham-
ber was defined, and 10 cigarettes could be set at a time.
All blood samples were collected from the abdominal
vena cava into heparinized tubes at the same time of
day (9:00–10:00 AM) and centrifuged at 1500 r.p.m. and4°C for 5 min. Separated plasma was stored at −70°C for
subsequent determination of blood nicotine concentra-
tions. The blood concentration of nicotine was measured
to reflect the intensity of exposure to smoke. Cigarette
smoke was sent for 10 min and then the box was venti-
lated with room air for 10 min. This procedure was
repeated 10 times at 1-h intervals such that the amount
of cigarette smoking per day in the rats was equal to in
heavy smokers who smoke equal to 30 cigarettes per day
[20]. The impact of passive smoking was evaluated by
measuring blood nicotine concentrations [21].
The length of femur and height of the lumbar
The length of the femur and the posterior height and
anterior height of the L4 were measured with a preci-
sion calliper (±0.02 mm; China Machine Building Inter-
national Corporation Hunan Co., Hunan, China). These
measurements were made in duplicate by the same
examiner. The results of the length of the femur were
expressed as the mean value of both femurs.
Bone densitometry
The bone mineral content (BMC) and density (BMD) at
femur neck and lumbar vertebrae (L4-L6) were mea-
sured ex-vivo by dual-energy X-ray absorptiometry
(DXA; Hologic QDR-4500A) equipped with appropriate
software for bone assessment in small animals [22].
The scan resolution was 1.0 × 1.0 mm and scan speed
was 10 mm/s. The measurements with repositioning
of the bones were repeated for three times to calculate
the Coefficients of variation (CV). The CV for BMC
and BMD on femur neck in our laboratory were 2.1% and
2.2%, and on L4-L6 were 0.9% and 0.8%, respectively. The
results of the BMC or BMD in femur neck were expressed
as the mean value of both femurs. Similarly to the femur
neck, the results of the BMC or BMD in lumbar spine
were expressed as the mean value of L4-L6.
Biomarkers of bone turnover
Serum osteocalcin concentration was measured by an
enzyme-linked immunosorbent assay (Rat MidTM Osteo-
calcin ELISA kit, IDS Inc., Fountain Hills, AZ, USA)
according to the manufacturer's instructions. The intra-
and inter-assay variations of this measurement in
our laboratory were 6.8% and 8.9%, respectively. Serum
b-ALP was measured by immunoassay using the Access
Ostase Assay (Beckman Access, Beckman Coulter Inc.,
Fullerton, CA, USA). The intra-assay and interassay
coefficients of variation were 4.1% and 5.2%, respectively.
Serum TRACP 5b level was measured by a solid phase
immunofixed enzyme activity assay (Rat TRACPTM
Assay, IDS Inc., Fountain Hills, AZ, USA) according to
the manufacturer's instructions to assess bone resorption.
Table 1 Body weight, femur length and L4 height
Group Control Smoke Smoke+ L-EPF Smoke+M-EPF Smoke+H-EPF
Initial weights(g) 353 ± 23 351 ± 28 351± 16 355 ± 25 352 ± 17
Final weights(g) 362 ± 22 360 ± 26 358± 27 368 ± 29 364 ± 28
Length of femur (mm) 39.85 ± 0.54 39.73 ± 0.46 39.18 ± 0.71 39.88 ± 0.59 39.57 ± 0.66
Anterior height of L4 (mm) 7.32 ± 0.28 7.30 ± 0.24 7.35 ± 0.29 7.33 ±0.30 7.31 ±0.26
Posterior height of L4 (mm) 7.63 ± 0.38 7.62 ± 0.35 7.68 ± 0.34 7.65 ± 0.29 7.70 ±0.41
Values are means (for 10 rats) with their standard deviation.
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in our laboratory were 4.9% and 7.3%, respectively.
Bone histomorphometry
The one-third proximal segment of left tibia was embed-
ded in methyl methacrylate (MMA) after Villanueva’s
staining. A 10-μm-thick mid-sagittal section was obtained
using a microtome (MR2065; Reichert-Jung, Heidelberg,
Germany). Histomorphometry variables were analyzed in
both trabecular bone and cortical bone using an image-
analyzing computer (Cosmozone 1 S; Nikon, Tokyo,
Japan) linked to a microscope. The parameters measuredFigure 1 BMD (A) and BMC (B) at the femur neck and lumbar vertebr
smoke-exposed rats were significantly lower than that in other groups. Sign
were founded in the 150 and 300 mg/kg/d EPF group receiving passive sm
group). *P< 0.05 compared to smoke-exposed rats; # P< 0.05 compared toincluded trabecular bone volume, trabecular number,
trabecular thickness, cortical thickness, BFR/BS (bone
formation rate), trabecular separation, osteoclast surface
per bone surface and osteoblast surface per bone sur-
face. Standard bone histomorphometrical nomenclatures,
symbols, and units were used as described in the report
of the American Society of Bone and Mineral Research
Histomorphometry Nomenclature Committee [23]. The
sections were also carefully polished, etched with a
solution of HCl 0.1 N for 60 s, and gold palladium-
coated for backscattered scanning electron microscopic
(SEM) analysis.a. BMD and BMC at the lumbar vertebrae and femur in the 4-month
ificantly higher BMD and BMC at the femur neck and lumbar vertebra
oking compared to the control group. Mean± SD (n= 10 in each
controls.
Figure 2 Levels of osteocalcin (A), b-ALP (B) and TRACP 5b (C)
in five groups. The smoke-exposed male rats had lower osteocalcin
concentration and b-ALP activity and higher TRACP 5b levels than
the controls. Mean± SD (n = 10 in each group). *P< 0.05 compared
to smoke-exposed rats.
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Biomechanical properties were estimated in a com-
pression test of the L4 performed by AG-IS Universal
Testing Instrument (Shanghai, Shimadzu, Japan) [21].
The L4 was compressed until failure along its longi-
tudinal axis at a displacement rate of 2 mm/min
using the flat-tipped pin 4.5 mm in diameter. Load–
displacement curves were recorded on-line and analyzed
for the following bone biomechanical properties: yield
load (the force causing the first bone damage), ultimate
load (the force at which fracture occurs), displacement
at yield (maximal bone deformation under elastic con-
ditions) and at ultimate (bone deformation at the frac-
ture point), stiffness (the slope of the linear, elastic
part of the load–displacement curve), and work to the
L4 failure.
Statistical analysis
Results of all measurements were presented as mean ±
S.D. for ten rats in each group. A one-way analysis of
variance (ANOVA) was first performed to determine
whether there were statistically significant (p < 0.05)
differences among the experimental groups. Further,
the Duncan’s multiple range post-hoc test was used for
comparisons between individual groups and to deter-
mine which means differed statistically significantly
(p < 0.05).
Results
Body weight, blood nicotine concentrations, femur length
and L4 height
The rats were weighed weekly throughout the whole
experiment. The initial weights and final weights are
shown in Table 1. At the beginning of the study and
during the 4-month experimental period there were no
statistically significant differences in the body weight of
rats among the five groups (P > 0.05). At termination,
the body weight of rats receiving passive smoking or/
and EPF was similar to that noted in the control group
reaching 362.3 ± 22.2 g. The mean water consumption
was 11.5 ±1.8 ml/100 g body weight/day. Total food and
water supply in smoke-exposed groups were similar to
that in the control groups.
The concentrations in the controls and the 4-month
smoke-exposed rats were 2.4 ± 1.3 ng/ml and 40.6 ±
5.9 ng/ml, respectively. The blood nicotine concentra-
tions in the 75, 150 and 300 mg/kg/d EPF groups receiv-
ing passive smoking were 39.2 ± 3.7 ng/ml, 40.7 ± 3.5 ng/
ml and 41.2 ± 3.9 ng/ml, respectively. The blood nicotine
concentration in the rats receiving passive smoking or/
and EPF was significantly higher than those in controls
(P < 0.05).
The femur length and the anterior height and poster-
ior height of L4 in the control rats were 39.85 ±0.54 mm, 7.32 ± 0.28 mm and 7.63 ± 0.38 mm, respect-
ively, after 4 months of the experiment. The femur
length and L4 height were unchanged by any treatment
(Table 1).
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BMD and BMC of the femur neck and lumbar vertebrae
are demonstrated in Figure 1. BMD and BMC of the
femur neck and lumbar vertebrae were lower (P < 0.05)
in the smoke-exposed rats compared to control groups
after 4 months of the experiment. There was no signifi-
cant difference in the BMD and BMC at the femur
neck and lumbar vertebrae between the controls and
75 mg/kg/day EPF groups receiving passive smoking.
The 150 or 300 mg/kg/day EPF groups receiving passive
smoking had greater BMD and BMC at the femur neck
and lumbar vertebrae than control groups.
Bone turnover
Figure 2 shows the results of the bone turnover mea-
surements. Significantly lower osteocalcin concentra-
tion and b-ALP activity and higher TRACP 5b levels
were found in the smoke-exposed male rats compared
to controls. There was no significant difference in
serum osteocalcin concentration and b-ALP activity and
TRACP 5b levels among the controls, 75, 150, and
300 mg/kg/d EPF groups receiving passive smoking
(P > 0.05) (Figure 2).
SEM and histomorphometric findings
Figure 3 displays five images obtained by SEM examin-
ation of the tibia. The rats of the control group revealed
normal compactness of the diaphysis and competent tra-
beculae (Figure 3A). The passive smoking animals showed
sparse, uniform thinning of the trabeculae resulting inFigure 3 SEM micrographs of the tibia. The rats of the control group re
trabeculae (A). The passive smoking animals showed sparse, uniform thinn
The passive smoking and L-EPF group exhibited significant remodeling pro
H-EPF (E) showed nearly essential features of normal bone.widened intertrabecular spaces (Figure 3B). The passive
smoking and L-EPF group exhibited significant remodel-
ing progress with mineralization (Figure 3C). The group
treated with M-EPF (Figure 3D) and H-EPF (Figure 3E)
showed nearly essential features of normal bone.
Results concerning bone histomorphometry of the
tibia are summarized in Figure 4. In the smoke-exposed
rats, trabecular bone volume, trabecular thickness, cor-
tical thickness, trabecular number, BFR/BS and osteo-
blast surface per bone surface were lower (by 43.5%,
24.2%, 12.5%, 52.7%, 39.4% and 25.4%, respectively),
whereas trabecular separation and osteoclast surface per
bone surface were greater (by 128.8 and 30.6%, respect-
ively) compared to the control group. Compared to con-
trol group, lower trabecular bone volume and BFR/BS
(bone formation rate) were found in the 75 mg/kg/d
EPF group receiving passive smoking. No differences
were noted in the other bone histomorphometry mea-
surements between this group and the control group. In
the 150 and 300 mg/kg/d EPF group receiving passive
smoking, greater osteoblast surface per bone surface was
noted, but there was no significant difference in the
other bone histomorphometry measurements, when
compared to the control group.
Biomechanical properties
The biomechanical properties of L4 are shown in Table 2.
The bone yield load, ultimate load, displacement at yield,
displacement at ultimate, stiffness and work to failure
were, respectively 23.8%, 26.5%, 9.2%, 21.9%, 21.8% andvealed normal compactness of the diaphysis and competent
ing of the trabeculae resulting in widened intertrabecular spaces (B).
gress with mineralization (C). The group treated with M-EPF (D) and
Figure 4 (See legend on next page.)
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Figure 4 Histomorphometric parameters of tibia. Significantly greater trabecular separation (F) and osteoclast surface per bone surface (H),
lower trabecular bone volume (A), trabecular thickness (B), trabecular number (C), cortical thickness (D), BFR/BS (E), osteoblast surface per bone
surface (G) were noted in the smoke-exposed male rats compared to controls. EPF returned the histomorphometric parameters to control levels.
Mean± SD (n = 10 in each group). *P< 0.05 compared to smoke-exposed rats; #P< 0.05 compared to controls.
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No significant difference of the biomechanical properties
of L4 was noted among the controls, 75, 150, and
300 mg/kg/d EPF groups receiving passive smoking.
Discussion
The damaging action of chronic smoke exposure on the
skeleton and its possible mechanisms have been extensively
studied by us and reported in details [24-31]. We demon-
strated that the BMD and BMC of the femur neck and
lumbar vertebrae were lower in 4-month smoke exposed
rats than in controls. Moreover, lower serum osteocalcin
concentration and activity of b-ALP and greater TRACP
5b level were noted in the passive smoking group, consist-
ent with the results of previous report [21,28,29]. These
results indicated that smoke exposure suppressed bone for-
mation and increased bone resorption. In addition, signifi-
cant lower trabecular bone volume, trabecular thickness,
trabecular number, cortical thickness, bone formation rate
and osteoblast surface per bone surface and significant
greater trabecular separation and osteoclast surface per
bone surface were found in the passive smoking groups.
Taking into account the observations made in the present
study and the previous reports [24,27,31] the damaging ac-
tion of smoke exposure on the skeleton might result from
its direct action. This mechanism involved stimulation of
bone resorption and inhibition of its formation through a
direct influence on both differentiation and activity of
osteoblastic and osteoclastic bone cells.
Chinese herbal medicine has been widely used for
thousands of years in the treatment of fracture and joint
diseases. EPF was found to have a preventive effect on
osteoporosis by ovariectomy rat models [16,32] and
exert a beneficial effect on preventing bone loss for post-
menopausal women [33]. Icariin is a major constituent
of flavonoids isolated from the herb Epimedium. TheTable 2 Biomechanical properties of L4 in five groups




Control 126.24 ± 8.01* 235.1 ± 38.6* 0.791 ± 0.
Smoke 96.24 ± 14.67 172.9 ± 15.9 0.721 ± 0.
Smoke+ L-EPF 117.43 ± 17.09* 225.1 ± 38.6* 0.782 ± 0.
Smoke+M-EPF 115.52 ± 15.12* 238.1 ± 36.2* 0.786 ± 0.
Smoke+H-EPF 128.52 ± 16.39* 245.8 ± 38.2* 0.795 ± 0.
Mean± SD (n = 10 in each group).
*P < 0.05 compared to smoke-exposed rats.previous studies reported that icariin can stimulate pro-
liferation and differentiation of human osteoblasts by
increasing production of BMP-2, BMP-4, NO synthesis,
promoting the ALP activity and type I collagen expres-
sion, subsequently regulating Cbfa1/Runx2, OPG, and
RANKL gene expressions [17,34-36]. Meanwhile, icariin
also was found to can inhibit osteoclast formation by
RANKL and macrophage-colony stimulating factor, and
inhibit osteoclast differentiation and bone resorption by
suppression of MAPKs/NF-κB regulated HIF-1α and
PGE(2) synthesis[37,38].
However, the beneficial influence of EPF on the skeleton
at the exposure to cigarette smoke has not been shown until
now. The enhanced serum osteocalcin concentration and
b-ALP activity due to EPF indicated an enhanced osteo-
blastic activity in the whole skeleton. Our findings about
TRACP 5b, would indicate that EPF can prevent the smoke-
induced increased osteoclast activities. The pattern of change
in bone turnover was consistent with the findings from pre-
viously published study on EPF in an ovariectomized rat
model [39]. Icariin, one of the major flavonoids in EPF
(77%), has been reported to stimulate proliferation of rat
bone marrow stromal cells and increase the number of col-
ony unit forming-fibroblasts staining positive for alkaline
phosphatase in a dose-dependent manner, whereas the
alkaline phosphatase activity, OC secretion, and calcium
deposition level of rat bone marrow stromal cells were
also increased by icariin in a dose-dependent manner,
suggesting a potential anabolic effect of icariin on bone
[40]. Furthermore, Genistein and Daidzein, the other two
flavonoids within EPFs (23%), have also been reported to
have a stimulatory effect on protein synthesis and on
alkaline phosphatase release by various types of osteo-
blast cells in vitro [41-43]. Thus, the beneficial effect of
EPF consisted in the stimulation of osteoblast activity as








051* 1.888± 0.245* 254.0 ± 64.4* 0.491 ± 0.045*
043 1.475± 0.136 198.6 ± 42.3 0.398 ± 0.054
052* 1.723± 0.167* 238.2 ± 54.7* 0.466 ± 0.039*
058* 1.779± 0.138* 248.2 ± 46.2* 0.465 ± 0.077*
060* 1.783± 0.196* 258.2 ± 35.5* 0.488 ± 0.063*
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osteoblast proliferation and inhibited the expression of
some key osteogenic (TGF-β1, BMP-2) and angiogenic
mediators (PDGF-AA, VEGF) in the in vitro experimental
model. In addition, Ma L et al. [45] reported that Calcium
accumulation, ALP activity, and mRNA levels of ALP,
bone sialoprotein (BSP), collagen type I α 1 (Col1αI), and
runt-related transcription factor 2 (Runx2) were signifi-
cantly decreased by treatment with nicotine, while osteo-
calcin transcripts decreased by treatment with nicotine.
Thus, nicotine may interact with EPF since nicotine
also regulates proliferation and differentiation of human
osteoblasts and modulates bone metabolism-associated
gene expression in osteoblast cells [44,46].
In this study, the 8-month rats were in the final phase
of bone mass formation (bone mass consolidation) and
its metabolic processes in the bone slow down. The
cellular mechanism behind the anabolic effect of EPF
has not been established clearly yet. EPF-treatment may
induce a positive bone balance in the remodeling cycle,
but this has not been shown directly by histomorphome-
try. Alternatively, part of the bone anabolic effect of
icariin or other EPF components may result from the
induction of bone formation by modelling. Such an
effect has been demonstrated already to be part of the
bone anabolic action of parathyroid hormone by Lindsay
and Dempster in iliac crest biopsies [47], and the same
may be true for icariin. Our study showed that EPF can
succeed to bring the histomorphometric parameters and
biomechanical properties back to control levels and
prevent from all of the adverse effects of smoke expos-
ure on bone. This study also showed that EPF can
exhibit a beneficial effect on preventing bone loss in pas-
sive smoking rats, which was shown by maintained
BMD and BMC at the femur neck and lumbar vertebrae
in the EPF treatment group compared with significantly
decreased BMD and BMC in the passive smoking group.
In addition, it is important to note that the higher mean
values of the densitometric parameters were found in
the EPF group receiving passive smoking than in the
passive smoking group or the control group. The alter-
native explanations for the increase in BMD may include
induction of periosteal and endocortical bone modeling
(increased cortical thickness), induction of trabecular
micro modeling and prevention of marrow cavity expan-
sion, etc. These results may suggest that EPF via its
positive effect on bone might also somewhat induce
bone modeling.
The influence of EPF on the bone mineral status and
bone turnover during the exposure to cigarette smoke
somewhat differed depending on EPF dose. Additional
daily consumption of 75 mg EPF/kg body wt was noted
to be sufficient in this regard; however, the daily dose
of 150 or 300 mg EPF/kg body wt may offer strongerprotection. The osteoblast surface and many static para-
meters of bone geometry indicated that the bone forma-
tion was dose dependent. The results suggested that
there was a bone formation inducing component in EPF
which induced a bone anabolic response independent of
its effect on bone resorption. As mentioned above this
could be in the form of induction of bone modeling,
which was independent of bone resorption.
The effects of EPF on bone have been reported [16].
Thus, this study has not a series of rats treated only with
EPF (without smoking). Considering how this medica-
tion could be used in the future, it would be necessary
to include an additional control group that is kept
under normal environment without smoke but receives
EPF. That is exactly what we are planning to do in the
near future.
Though the present study demonstrate that EPF has
a protective effect on the skeleton in smoke-exposed
rats, it is not clear whether EPF has a protective effect
on the cardio-respiratory effects of smoking and the
increased risk of cancer up to now. Even if the smoker
can inhibit their bone loss by taking this medicine,
smoking also is not ok. According the 2004 Surgeon's
General Report, every smoker lives on average 13–
14 years less than non-smokers. Smoking also causes
cancer, damages organs, and weakens the immune
system. In addition, smoking can also harm those
nearby, in terms of second-hand smoke. Therefore, it
would still be recommended to quit smoking or never
initiate it in the first place.
Conclusion
In summary, the present study, in a male rat model of
relatively high human exposure to cigarette smoke, sug-
gests that EPF supplementation during chronic exposure
to cigarette smoke can prevent from smoke-induced
bone loss by stimulating bone formation and inhibiting
bone turnover and bone resorption, without resulting in
a detectable effect on the bone.
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